United-Guardian, Inc. — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015; comparative period is Q1 2014. United-Guardian develops, manufactures, and markets personal-care and cosmetic ingredients, pharmaceutical and medical products, and specialty industrial products.
Financial performance
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Net sales | $4.372 million | $3.959 million | +10.4% |
| Gross profit | $2.693 million | $2.527 million | +6.6% |
| Gross margin | 61.6% | 63.8% | Down 2.2 percentage points |
| Operating income | $2.066 million | $1.911 million | +8.1% |
| Net income | $1.461 million | $1.336 million | +9.3% |
| Diluted and basic EPS | $0.32 | $0.29 | +$0.03 |
| Net cash from operations | $1.810 million | $0.892 million | +$0.918 million |
Operating margin was approximately 47.3%, versus 48.3% a year earlier; net margin was approximately 33.4%, versus 33.7%. Cost of sales rose to 38.4% of sales from 36.2%, largely reflecting a less favorable product mix. Operating expenses increased 1.9%. Other income was $53,454, down from $58,221: higher investment income was more than offset by the absence of the prior-year final RENACIDIN supplier settlement payment. The effective tax rate was approximately 31%, versus 32%.
Liquidity, cash flow, and balance sheet
- At March 31, 2015, cash and cash equivalents were $977,493 and marketable securities were $12.342 million. Total current assets were $16.990 million and current liabilities were $1.713 million; working capital was $15.277 million.
- Working capital increased $1.589 million from December 31, 2014, while the current ratio declined to 9.9:1 from 15.0:1, primarily because income taxes payable increased to $652,150.
- Operating cash flow was $1.810 million. Investing activities used $2.856 million, mainly for purchases of marketable securities; capital expenditures were $2,143. Cash decreased $1.046 million during the quarter.
- No debt or financing activity is reported. Stockholders’ equity was $16.263 million. No dividends were paid in either comparative quarter.
Material changes and management outlook
- Personal-care sales increased 12.0%, driven by higher sales to the largest marketing partner and other partners. Pharmaceutical sales increased 27.4%, principally because RENACIDIN sales in Q1 2014 were comparatively low. Medical sales declined 7.0%, and industrial and other sales declined 31.4%.
- Management attributed personal-care growth to demand, particularly in Asia, partner inventory replenishment, and order timing. Approximately 65% of products are sold to end users outside the United States; Ashland Specialty Ingredients is the largest marketing partner.
- Management expects working capital to support operating needs for at least the next 12 months and does not expect significant capital expenditures for the remainder of 2015. It expects to use cash for dividends, marketable-security purchases, and other opportunities, but provided no quantified earnings or revenue guidance.
- The company was working with a new supplier on a single-dose RENACIDIN presentation. FDA review, initially expected to finish by the end of Q1 2015, could extend to June 2015; management hoped to launch in Q1 2016, subject to approval timing. It expected current-form inventory to be adequate until then. RENACIDIN had previously been unavailable because of its sole supplier’s regulatory and manufacturing problems.
- Other disclosed risks include competition, product acceptance and development, intellectual-property changes, economic and industry conditions, and regulatory or legislative changes. Management reported effective disclosure controls and no material change in internal control over financial reporting. No legal proceedings or off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Whether the anticipated FDA review and RENACIDIN single-dose launch timetable were achieved, and whether current-form supply remained adequate.
- Whether sales growth continued beyond the quarter, particularly given order timing, partner inventory replenishment, and reliance on the largest marketing partner.
- Whether product mix continues to pressure gross margin, especially as lower-margin RENACIDIN and certain LUBRAJEL products contribute to sales.
- Whether receivables, taxes payable, and the composition of cash and marketable securities materially change; Q1 operating cash flow benefited from working-capital movements.
- Whether the company’s anticipated dividend payments and investment decisions are reflected in subsequent filings; no Q1 dividend was paid.